Kegg Pathway: Purine metabolism

KEGG ID: 00230

Reference Diagram

KEGG Diagram for Purine metabolism

Rat

There are 97 IPI Records from this pathway found in Rattus norvegicus.

Location of Purine metabolism proteins on Rat Genome

IPI Record Position
1: Ada 3:154636530-154660637
2: Adcy10 13:81225305-81303915
3: Adcy1_predicted 14:87812093-87923402
4: Adcy2 17:4543509-5039775
5: Adcy3 6:27118400-27202275
6: Adcy4 15:33930534-33946352
7: Adcy5 11:67290968-67437468
8: Adcy6 7:137339933-137360809
9: Adcy7 19:20052391-20091871
10: Adcy8 7:101957807-102210346
11: Adk 15:3071412-3458891
12: Ak1 :-
13: Ak2 5:148156751-148173160
14: Ak3l1 5:122062359-122206976
15: Ampd1 2:198308460-198331000
16: Ampd3 1:168533492-168568291
17: Atic 9:70676744-70696865
18: Cant1 10:108406740-108411414
19: Dck 14:20886689-20904305
20: Dguok_predicted 4:117697971-117725328
21: Enpp1 1:21223674-21287411
22: Enpp2 7:91296289-91377765
23: Enpp3 1:21087399-21159922
24: Entpd1 1:245832187-245887345
25: Entpd2 3:3564380-3569800
26: Entpd3 8:125542934-125573947
27: Entpd6 3:141385480-141407860
28: Fhit 15:16518688-17299364
29: Gda 1:224579743-224655354
30: Gmpr 17:25147730-25185385
31: Gmps 2:153804512-153840009
32: Gucy1a2 8:113243-262544
33: Gucy1a3 2:173755007-173818430
34: Gucy1b2 15:41620373-41689522
35: Gucy1b3 2:173685446-173734726
36: Gucy2c 4:173740207-173791106
37: Gucy2e 10:56012236-56027290
38: Gucy2f X:36367528-36469112
39: Guk1 10:45489206-45497360
40: Hprt X:139929647-139961620
41: Impdh1_predicted 4:56075236-56090928
42: Impdh2 8:113607025-113611615
43: IPI00371206 12:46491499-46540008
44: MGC93997 2:190165356-190192807
45: Nme1 10:82591705-82601075
46: Nme2 10:82582766-82588269
47: Nme3 10:14145488-14146444
48: Nme6 8:114205318-114212486
49: Nme7 13:80064602-80213993
50: Npr1 2:182724916-182740242
51: Npr2 5:60107563-60127960
52: Nt5c1a_predicted 5:142509315-142524280
53: Nt5e 8:93591280-93635456
54: Nudt9 14:6809091-6840664
55: Paics 14:33493300-33505359
56: Pde10a 1:46392900-46852719
57: Pde1a 3:62671556-62928487
58: Pde1b 7:142401489-142427626
59: Pde1c 4:84937137-85447998
60: Pde2a 1:158921798-159013829
61: Pde3a 4:178658896-178930417
62: Pde3b 1:172409282-172577108
63: Pde4a 8:20192744-20241581
64: Pde4b 5:123067178-123533832
65: Pde4d 2:40496293-41308470
66: Pde5a 2:219409490-219550910
67: Pde6d_predicted 9:85307908-85352852
68: Pde6h 4:174009860-174014405
69: Pde8a 1:137415852-137544337
70: Pde8b 2:25352725-25469210
71: Pde9a 20:9872154-9899505
72: Pklr 2:181214402-181223512
73: Pkm2 8:63486490-63508245
74: Pnpt1 14:110130420-110161035
75: Pola2 1:208573153-208597195
76: Pold1 1:95010719-95021686
77: Pold2 14:86535757-86541920
78: Pold3 1:157453059-157490563
79: Pold4 1:206815462-206817131
80: Pole2_predicted 6:91156670-91180121
81: Pole3 7:115569846-115570283
82: Pole4_predicted 4:116860980-116862195
83: Polr2b_predicted 14:33069968-33107600
84: Polr2f 7:117122838-117137656
85: Polr2g 1:211462321-211465653
86: Polr3c 2:191511970-191527849
87: Ppat 14:33509364-33543743
88: Prim2 9:32206274-32423506
89: Prps1 X:128249845-128271891
90: Prps2 X:47274362-47315274
91: RGD1559671_predicted :-
92: Rpo1-2 3:116706483-116730946
93: Rpo1-4 4:105187426-105251391
94: Rrm2 :-
95: Uox 2:244795550-244832144
96: Xdh 6:21417685-21590015
97: Znrd1 20:1687850-1691468

Mouse

There are 97 IPI Records from this pathway found in Mus musculus.

Location of Purine metabolism proteins on Mouse Genome

IPI Record Position
1: 5NT1A_MOUSE 4:122703861-122718510
2: Ada 2:163418025-163441618
3: Adcy1 11:6963492-7078509
4: Adcy2 13:69087426-69466728
5: Adcy3 12:4133468-4214742
6: Adcy4 14:54723163-54738090
7: Adcy5 16:35074624-35224118
8: Adcy6 15:98418007-98435667
9: Adcy7 8:91162508-91220066
10: Adcy8 15:64528707-64751833
11: Adcy9 16:4202773-4335034
12: Adk 14:19841183-20237107
13: Adsl 15:80775774-80798202
14: Adss 1:179599853-179633184
15: Adssl1 12:113067901-113089165
16: Ak1 2:32451571-32457488
17: Ak2 4:128495528-128513833
18: Ak3l1 4:100917209-100964927
19: Ampd1 3:103203157-103228775
20: Ampd2 3:108202118-108214707
21: Ampd3 7:110563781-110603586
22: Aprt 8:125460727-125462950
23: Atic 1:71490367-71512612
24: Cant1 11:118222379-118235176
25: Dck 5:89839588-89857838
26: Dguok 6:83445877-83472627
27: Ecgf1 15:89199698-89204806
28: Enpp1 10:24330827-24401518
29: Enpp2 15:54668984-54750085
30: Enpp3 10:24463318-24525509
31: Entpd1 19:40664912-40666307
32: Entpd2 2:25217912-25223324
33: Entpd3 9:120388541-120417015
34: Entpd4 14:68290504-68320600
35: Entpd5 12:85263605-85295224
36: Fhit 14:8367196-9215384
37: Gart 16:91510268-91535812
38: Gda 19:21370247-21539758
39: Gmpr 13:45518429-45557352
40: Gmpr2 14:54626307-54633271
41: Gmps 3:64064072-64107007
42: Gucy1a2 9:3532803-3894711
43: Gucy1a3 3:82178350-82231714
44: Gucy1b2 14:61346786-61410399
45: Gucy1b3 3:82119182-82159998
46: Gucy2e 11:69039230-69053217
47: Guk1 11:59000070-59008011
48: Hprt1 X:49232760-49266287
49: Impdh1 6:29150447-29166360
50: Impdh2 9:108418594-108423667
51: Itpa 2:130359051-130373055
52: mt-Atp6 M:7927-8607
53: mt-Atp8 M:7766-7969
54: Nme1 11:93773067-93784347
55: Nme2 11:93765906-93772346
56: Nme3 17:24624100-24625122
57: Nme4 17:25819339-25823108
58: Nme5 18:34687524-34703487
59: Nme6 9:109690200-109700367
60: Nme7 1:166149554-166239755
61: Npr1 3:90536519-90552265
62: Npr2 4:43653035-43672344
63: Nt5c1b 12:10396052-10416178
64: Nt5c2 19:46941139-47015619
65: Nt5c3 6:56811982-56853407
66: Nt5e 9:88125533-88169982
67: Nudt2 4:41653819-41669597
68: Nudt5 2:5762306-5786008
69: Nudt9 5:104287299-104305669
70: Paics 5:78026186-78042284
71: Papss1 3:131502197-131580977
72: Papss2 19:32686002-32733184
73: Pde10a 17:8639919-8824822
74: Pde1a 2:79635292-79930314
75: Pde1b 15:103331332-103358086
76: Pde1c 6:55999382-56291970
77: Pde2a 7:101295530-101386640
78: Pde3a 6:141211675-141461757
79: Pde3b 7:114206462-114327893
80: Pde4a 9:20916193-20962030
81: Pde4b 4:101753153-102103755
82: Pde4d 13:110153332-111072352
83: Pde5a 3:122721180-122848174
84: Pde6d 1:88374186-88413672
85: Pde6g 11:120263700-120269573
86: Pde6h 6:136918719-136933052
87: Pde7a 3:19416831-19503473
88: Pde7b 10:20089834-20308624
89: Pde8a 7:81087251-81208046
90: Pde8b 13:96125204-96324254
91: Pde9a 17:31114961-31205019
92: Pfas 11:68801895-68820032
93: Pklr 3:89222069-89231560
94: Pkm2 9:59454614-59477381
95: Pnp1 14:49777557-49875363
96: Pnpt1 11:29030748-29061828
97: Pola1 X:89557486-89884874
98: Pola2 19:5940546-5964170
99: Pold1 7:44400831-44411478
100: Pold2 11:5772183-5778295
101: Pold3 7:99956195-99995586
102: Pold4 19:4231937-4233631
103: Pole 5:110526686-110577755
104: Pole2 12:70120384-70146795
105: Pole3 4:62009017-62011429
106: Pole4 6:82617084-82618497
107: Polr2a 11:69550305-69574488
108: Polr2b 5:78385259-78424099
109: Polr2c 8:97746685-97759818
110: Polr2d 18:31932169-31939652
111: Polr2e 10:79439079-79442839
112: Polr2f 15:78968610-78979021
113: Polr2g 19:8860173-8865621
114: Polr2h 16:20631460-20635808
115: Polr2i 7:29940834-29942146
116: Polr2j 5:136401361-136407566
117: Polr2k X:35214444-35214620
118: Polr3a 14:23281170-23319474
119: Polr3b 10:84052236-84156977
120: Polr3c 3:96796933-96812870
121: Polr3f 2:144219186-144233220
122: Polr3g 13:82151180-82188304
123: Polr3gl 3:96663279-96679548
124: Polr3h 15:81715483-81753468
125: Polr3k 2:181793852-181799571
126: Ppat 5:77989918-77993045
127: Prim1 10:127418141-127432979
128: Prim2 1:33398361-33614326
129: Prps1 X:135802977-135822503
130: Prps2 X:162690438-162726804
131: Prune 3:95339078-95367480
132: Rfc5 5:117640177-117650063
133: Rpo1-1 17:45707509-45711547
134: Rpo1-2 2:128792436-128818035
135: Rpo1-4 6:71838582-71908875
136: Rrm1 7:102315638-102342746
137: Rrm2 12:25297333-25303186
138: Rrm2b 15:37868541-37905644
139: Sacy 1:167339845-167413448
140: Uox 3:146534535-146568869
141: Xdh 17:73788790-73855081
142: Znrd1 17:36562411-36566535

Human

There are 97 IPI Records from this pathway found in Homo sapiens.

Location of Purine metabolism proteins on Human Genome

IPI Record Position
1: ADA 20:42681577-42713797
2: ADCY1 7:45580646-45729237
3: ADCY2 5:7449345-7883194
4: ADCY3 2:24895542-24996212
5: ADCY4 14:23857395-23874117
6: ADCY5 3:124486089-124650082
7: ADCY6 12:47446248-47464157
8: ADCY7 16:48879323-48909536
9: ADCY8 8:131861736-132123854
10: ADCY9 16:3952658-4106187
11: ADK 10:75580971-76139067
12: ADSL 22:39072466-39092929
13: ADSS 1:242638419-242682059
14: ADSSL1 14:104261579-104284690
15: AK1 9:129668580-129679843
16: AK2 1:33246173-33275180
17: AK5 1:77520250-77798242
18: AK7 14:95928201-96024866
19: ALLC 2:3683685-3728131
20: AMPD1 1:115017245-115039762
21: AMPD2 1:109963982-109976198
22: AMPD3 11:10428800-10485702
23: APRT 16:87403378-87405843
24: ATIC 2:215885036-215922724
25: CANT1 17:74499394-74517444
26: DCK 4:72078256-72115477
27: DGUOK 2:74007461-74039596
28: ECGF1 22:49311047-49315321
29: ENPP1 6:132170849-132257988
30: ENPP2 8:120638507-120720260
31: ENPP3 6:132000135-132110243
32: ENTPD1 10:97461526-97619442
33: ENTPD2 9:139062374-139068326
34: ENTPD3 3:40403689-40445113
35: ENTPD4 8:23299386-23371153
36: ENTPD5 14:73502946-73552387
37: ENTPD6 20:25124358-25155365
38: ENTPD8 9:139448638-139456089
39: FHIT 3:59712992-60497735
40: GART 21:33798108-33837068
41: GDA 9:73954113-74058296
42: GMPR 6:16346790-16403757
43: GMPR2 14:23771488-23778285
44: GMPS 3:157071019-157138215
45: GUCY1A2 11:106063120-106394381
46: GUCY1A3 4:156807706-156872926
47: GUCY1B3 4:156899661-156951636
48: GUCY2C 12:14656843-14740696
49: GUCY2D 17:7846713-7864383
50: GUCY2F X:108502791-108611957
51: GUK1 1:226394286-226403308
52: HPRT1 X:133421849-133462364
53: IMPDH1 7:127819568-127837542
54: IMPDH2 3:49036774-49041879
55: ITPA 20:3138006-3152511
56: NME1 17:46585919-46604103
57: NME2 17:46585919-46604103
58: NME4 16:387193-390754
59: NME6 3:48310595-48317852
60: NME7 1:167368393-167603829
61: NP 14:20007409-20015082
62: NPR1 1:151917737-151933092
63: NPR2 9:35782151-35799729
64: NT5C 17:70637919-70639472
65: NT5C1A 1:39897380-39910297
66: NT5C1B 2:18599470-18634319
67: NT5C3 7:33020267-33068934
68: NT5E 6:86216528-86262215
69: NT5M 17:17147421-17191696
70: NUDT2 9:34319504-34333709
71: NUDT5 10:12247330-12278129
72: NUDT9 4:88562759-88599630
73: PAICS 4:56996698-57022282
74: PAPSS1 4:108754272-108860868
75: PAPSS2 10:89409350-89497442
76: PDE10A 6:165660766-165995578
77: PDE11A 2:178201060-178681312
78: PDE1A 2:182720051-183095348
79: PDE1C 7:31759215-32304872
80: PDE2A 11:71964834-72063113
81: PDE3B 11:14621913-14848926
82: PDE4A 19:10388449-10441306
83: PDE4B 1:66030785-66612850
84: PDE4C 19:18182010-18227229
85: PDE4D 5:58305622-59320301
86: PDE5A 4:120635000-120769429
87: PDE6D 2:232305380-232354217
88: PDE6G 17:77227655-77234018
89: PDE6H 12:15017245-15026066
90: PDE7A 8:66793867-66863886
91: PDE7B 6:136214527-136558405
92: PDE8A 15:83324675-83483371
93: PDE8B 5:76542462-76759837
94: PDE9A 21:42946931-43068685
95: PFAS 17:8093338-8114534
96: PKLR 1:153526254-153537849
97: PKM2 15:70278424-70310738
98: PNPT1 2:55715971-55774463
99: POLA1 X:24621957-24925024
100: POLA2 11:64786006-64821663
101: POLD1 19:55579408-55613082
102: POLD2 7:44120812-44128238
103: POLD3 11:73981277-74031413
104: POLD4 11:66875597-66877593
105: POLE 12:131710421-131923460
106: POLE2 14:49180028-49224685
107: POLE3 9:115209336-115212773
108: POLE4 2:75039283-75050366
109: POLR1A 2:86107891-86186479
110: POLR1B 2:113016084-113051879
111: POLR1C 6:43592769-43605071
112: POLR1D 13:27092903-27139548
113: POLR2A 17:7328422-7358653
114: POLR2B 4:57538665-57592081
115: POLR2C 16:56054080-56063422
116: POLR2D 2:128320710-128332174
117: POLR2E 19:1039166-1046314
118: POLR2F 22:36679665-36694653
119: POLR2G 11:62285591-62290757
120: POLR2H 3:185562254-185568989
121: POLR2I 19:41296452-41298088
122: POLR2J 7:101900555-101906386
123: POLR2K 8:101232015-101235406
124: POLR2L 11:829754-832529
125: POLR3A 10:79404913-79459309
126: POLR3B 12:105275619-105428104
127: POLR3GL 1:144167593-144181744
128: POLR3H 22:40251754-40270412
129: POLR3K 16:36405-43608
130: PPAT 4:56954288-56996602
131: PRIM1 12:55411647-55432349
132: PRIM2 6:57287562-57620646
133: PRPS1 X:106758385-106780908
134: PRPS1L1 7:18032974-18033927
135: PRPS2 X:12719452-12752262
136: PRUNE 1:149247577-149274813
137: RFC5 12:116938893-116954421
138: RRM1 11:4072587-4116681
139: RRM2 2:10179906-10188996
140: RRM2B 8:103285908-103320522
141: SAC 1:166045506-166149964
142: XDH 2:31410691-31491117
143: ZNRD1 6:30166458-30169822

Google Scholar

Recent Literature

Role of adenosine A2 receptors in regulation of cerebral blood flow during induced hypotension.

J Cereb Blood Flow Metab. 2009 Nov 18;
Kusano Y, Echeverry G, Miekisiak G, Kulik TB, Aronhime SN, Chen JF, Winn HR

The mechanisms responsible for vascular autoregulation in the brain during changes in mean arterial blood pressure are ambiguous. Potentially, adenosine, a Purine nucleoside and potent vasodilator, may be involved as earlier studies have documented an increase in brain adenosine concentrations with cerebral ischemia and hypotension. Consequently, we tested the hypothesis that adenosine is involved in vasodilatation during hypotension within the autoregulatory range (>50 mm Hg) by exposing adenosine 2a receptor (A2aR) knockout and wild type (WT) mice to short (2 to 5 mins) periods of hypotension. We found that autoregulation was significantly (P<0.05) impaired by 29% in A2a knockout mice as compared with WT animals. Furthermore, the A2R antagonist (A2a>A2b:10-85>1), ZM-241385, in a dose (1, 5, 10 mg/kg, intraperitoneally)-related manner, attenuated autoregulation in WT mice. In knockout mice treated with ZM-2413585 (5 and 10 mg/kg), autoregulation was further impaired indicating that A2b receptors also participated in cerebral vasodilatation. Treatment with dipyridamole (1.0 mg/kg) that increases extracellular concentrations of adenosine improved autoregulation in the A2aR knockout mice. We would conclude that adenosine through both A2a and A2b receptors is involved in physiologic vascular regulation during hypotension even within the autoregulatory range.Journal of Cerebral Blood Flow & metabolism advance online publication, 18 November 2009; doi:10.1038/jcbfm.2009.244.

Identification of subspecies specific genes differentially expressed in procyclic forms of Trypanosoma brucei subspecies.

Infect Genet Evol. 2009 Nov 10;
Simo G, Queiroz R, Herder S, Cuny G, Hoheisel J

Trypanosoma brucei subspecies undergo establishment and maturation in tsetse flies mid-gut and salivary glands respectively. Successful establishment of trypanosomes in tsetse mid-gut as well as their migration to saliva gland depends on the ability of these parasites to adapt rapidly to new environmental conditions and to negotiate the physical barriers. To identify subspecies specific genes which are differentially regulated during the establishment of Trypanosoma brucei subspecies in tsetse flies mid gut, a comparative genomic analysis between different Trypanosoma brucei subspecies was performed using microarrays containing about 23 040 Trypanosoma brucei shotgun fragments. The whole genome analyses of RNA expression profiles revealed about 274 significantly differentially expressed genes between Trypanosoma brucei subspecies. About 7% of the differentially regulated clones did not match to any Trypanosoma brucei predicted genes. Most of the differentially regulated transcripts are involved in transport across cell membrane and also in the Purines metabolism. The genes selectively up regulated in Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense (human infective Trypanosoma brucei) like snoRNA and HSP70 are expressed in response to stress. The high failure rate in the process of establishment and maturation of Trypanosoma brucei gambiense during cyclical transmission in tsetse flies may result from the incapacity of this parasite to regulate its growth due to the expression of a variety of chaperones or heat shock proteins. Genes selectively up regulated in Trypanosoma brucei brucei like NT8.1 nucleoside/nucleobase transporters and S-adenosylmethionine synthetase may favor the establishment of this subspecies in tsetse mid gut. These genes appear as potential targets for investigations on the development of vaccine blocking the transmission of trypanosomes in tsetse flies.

Specific Chemotherapy of Chagas Disease: Relevance, Current Limitations and New Approaches.

Acta Trop. 2009 Nov 6;
Urbina JA

A critical review of the development of specific chemotherapeutic approaches for the management of American Trypanosomiasis or Chagas disease is presented, including controversies on the pathogenesis of the disease, the initial efforts that led to the development of currently available drugs (nifurtimox and benznidazole), limitations of these therapies and novel approaches for the development of anti-Trypanosoma cruzi drugs, based on our growing understanding of the biology of this parasite. Among the later, the most promising approaches are ergosterol biosynthesis inhibitors such as posaconazole and ravuconazole, poised to enter clinical trials for chronic Chagas disease in the short term; inhibitors of cruzipain, the main cysteine protease of T. cruzi, essential for its survival and proliferation in vitro and in vivo; bisphosphonates, metabolic stable pyrophosphate analogs that have trypanocidal activity through the inhibition of the parasite's farnesyl-pyrophosphate synthase or hexokinase; inhibitors of trypanothione synthesis and redox metabolism and inhibitors of hypoxanthine-guanine phosphoribosyl- transferase, an essential enzyme for Purine salvage in T. cruzi and related organisms. Finally, the economic and political challenges faced by development of drugs for the treatment of neglected tropical diseases, which afflict almost exclusively poor populations in developing countries, are analyzed and recent potential solutions for this conundrum are discussed.

The malate synthase of Paracoccidioides brasiliensis Pb01 is required in the glyoxylate cycle and in the allantoin degradation pathway.

Med Mycol. 2009 Nov; 47(7): 734-44
Zambuzzi-Carvalho PF, Cruz AH, Santos-Silva LK, Goes AM, Soares CM, Pereira M

In the present study, we examined the characteristics of cDNA, the regulation of the gene expression of Paracoccidioides brasiliensis MLS (Pbmls), and the enzymatic activity of the protein P. brasiliensis MLS (PbMLS) from the P. brasiliensis Pb01 isolate. Pbmls cDNA contains 1617 bp, encoding a protein of 539 amino acids with a predicted molecular mass of 60 kDa. The protein presents the MLSs family signature, the catalytic residues essential for enzymatic activity and the peroxisomal/glyoxysomal targeting signal PTS1. The high level of Pbmls transcript observed in the presence of two-carbon (2C) sources suggests that in P. brasiliensis, the primary regulation of carbon flux into the glyoxylate cycle (GC) was at the level of the Pbmls transcript. The gene expression, protein level, and enzymatic activity of Pbmls were highly induced by oxalurate in the presence of glucose and by proline in the presence of acetate. In the presence of glucose, the gene expression, protein level, and enzymatic activity of Pbmls were mildly stimulated by proline. Our results suggested that PbMLS condenses acetyl-CoA from both 2C sources (GC) and nitrogen sources (from proline and Purine metabolism) to produce malate. The regulation of Pbmls by carbon and nitrogen sources was reinforced by the presence of regulatory motifs CREA and UIS found in the promoter region of the gene.

Allium sativum L. extract prevents methyl mercury-induced cytotoxicity in peripheral blood leukocytes (LS).

Food Chem Toxicol. 2009 Oct 29;
Abdalla FH, Bellé LP, De Bona KS, Bitencourt PE, Pigatto AS, Moretto MB

Adenosine deaminase (ADA) is involved in Purine metabolism and plays a significant role in the immune system. The focus of this investigation was to examine the effects of low concentrations of organic mercury on ADA activity in human leukocytes and to investigate the relationship between these effects and cell death. We have examined the protective potential effects of Allium sativum extract (GaE) against Methylmercury (MeHg)-induced cytotoxic effects on human leucocytes under in vitro conditions. MeHg (0.05-10muM) significantly decreased leukocyte viability (58.97% for MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide) and 51.67% for Alamar Blue (AB) and this decrease was positively correlated to the MeHg-induced inhibition of ADA activity. N-acetylcysteine (NAC) and GaE prevented both the MeHg-induced cytotoxic effects on leukocytes according to MTT and AB assays and the effects on the ADA activity. The present results suggest that the protective effects of GaE against MeHg-induced leukocyte damage is related to the removal of oxidant species generated in the presence of MeHg due to the antioxidant efficacy of garlic constituents. It is important to point out that the intense presence of ADA in Leukocyte suspension (LS) highlights the relevant effects in the immune system and in vitro cytotoxicity of MeHg exposure.

Physiological effects of high- and low-voltage pulse combinations for gene electrotransfer in muscle.

Hum Gene Ther. 2008 Nov; 19(11): 1249-60
Hojman P, Gissel H, Andre FM, Cournil-Henrionnet C, Eriksen J, Gehl J, Mir LM

Gene transfer by electroporation is gaining momentum now that high-level, long-term expression of transgenes is being obtained. Several different pulse regimens are efficient, yet little information is available about the physiological muscular response to gene electrotransfer. This paper provides a comprehensive evaluation of the physiological and molecular effects on host tissue after DNA electrotransfer. We have tested several pulse regimens with special emphasis on the pulse combination of a short (100 microsec) high-voltage (HV) pulse followed by a long low-voltage (LV) pulse used for DNA electrotransfer, comparing it with 8 HV pulses designed to ensure extensive permeabilization of the muscle membrane. Using both mouse and rat skeletal muscle tissue, we investigated cell permeabilization by the 51Cr-labeled EDTA assay, lactate dehydrogenase release, Na+ and Ca2+ influx, K+ efflux, ATP release, and water content, as well as muscle function both in vivo and ex vivo, Hsp70 induction, and histology. In all these assays, the HVLV pulse combination gave rise to minimal disturbance of cell function, in all cases significantly different from results when using 8 HV pulses. The evaluated parameters were normalized after 1 week. The addition of DNA caused significantly more transmembrane exchange, and this may be due to entrance of the DNA through the membrane. In conclusion, this study comprehensively documents the immediate effects of DNA electrotransfer and shows that only slight cell disturbances occur with the HVLV pulses used for gene transfer. This is highly important, as minimal perturbation of cell physiology is essential for efficient transgene expression.

Replication of the 5 Novel Loci for Uric Acid Concentrations and Potential Mediating Mechanisms.

Hum Mol Genet. 2009 Oct 27;
van der Harst P, Bakker SJ, de Boer RA, Wolffenbuttel BH, Johnson T, Caulfield MJ, Navis G

Uric acid is the final catabolic product of Purine metabolism and elevated levels are associated with diabetes and cardiovascular disease. A recent meta-analysis of genome-wide association studies totalling 28,141 participants identified 5 novel loci associated with serum uric acid levels. In our population based cohort of 7,795 subjects we replicated 4 of these 5 loci; PDZK1 (rs12129861 P=1.07x10(-3)), GCKR (rs780094 P=4.83x10(-4)), SLC16A9 (rs742132 P=0.047), and SLC22A11 (rs17300741 P=6.13x10(-3)), but not LRRC16A (rs742132 P=0.645). Serum uric acid concentration is a complex trait, closely associated to renal uric acid handling (fractional uric acid excretion; P< 1 x 10(-300)), renal function (serum creatinine; P< 1 x 10(-300)), and the metabolic syndrome (including fasting insulin; P=2.48x10(-232), insulin resistance; P=2.51x10(-258), waist circumference; P< 1 x 10(-300)), and systolic blood pressure (P=1.93 x 10(-219)). Together these factors explain 67% of the variance in uric acid levels. Therefore, we sought to determine the potential contribution of these factors to the association of these novel loci with uric acid levels, by including them as additional explanatory variables in our analyses, and by considering them as alternative response variables. The association with the GCKR locus is attenuated by serum triglycerides and fractional uric acid excretion. We also observed the GCKR locus to be associated with total cholesterol (P= 7.52x10(-6)), triglycerides (P=2.65x10(-9)), fasting glucose (P=0.011), fractional uric acid excretion (P=3.36 x10(-5)), and high-sensitive CRP (P=1.18x10(-3)) also after adjusting for serum UA levels. We argue that GCKR locus affects serum UA levels through a factor that also affects triglycerides.

Tenofovir coadministration is not associated with lower unboosted atazanavir plasma exposure in the clinical setting.

J Acquir Immune Defic Syndr. 2009 Nov 1; 52(3): 431-2
Calcagno A, Bonora S, Tettoni MC, D'Avolio A, Perri GD, Lanzafame M, Penco G

Substitution of theophylline slow-release formulations according to the rebate contracts in the German statutory health insurance.

Arzneimittelforschung. 2009; 59(9): 476-81
Weissenfeld J, Lüngen M, Stock S, Drabik A, Gerber A

On the basis of the rebate contracts between individual statutory health insurance funds and pharmaceutical enterprises, the generic substitution of prescribed medications is economically attractive and is advocated for statutory health insurees in Germany. In addition to the drugs whose substitution can be considered to be uncritical, rebate contracts also include controversial substances such as the bronchodilator theophylline (CAS 58-55-9), which has a narrow therapeutic range and should only be substituted under certain conditions. The objective of this article was to check the safety of the substitution of theophylline by means of a comparative evaluation of bioequivalence studies carried out on theophylline slow-release preparations. A systematic literature search was carried out in the MEDLINE database. The search terms used were combinations of the following key words: theophylline, generics, bioequivalence, substitution, brand and non-brand. In addition, a manual search was performed in the reference lists of the relevant articles. Only articles that were published between January 1, 1988 and August 30, 2008 were to be included. Five studies conformed to the inclusion and exclusion criteria. Two of the studies came to the conclusion that the preparations analysed were bioequivalent. In the remaining three studies there was no bioequivalence found between the preparations and the reference product. Because of the heterogeneity of study outcomes no metanalysis could be performed. On the basis of the studies analysed the conclusion can be drawn that a theophylline slow-release preparation should only be substituted under close monitoring by a physician because of the many factors which can adversely affect serum levels, such as the narrow therapeutic range of the active ingredient, the patient's metabolisation rate or the different galenics of the preparations. Nevertheless, the question remains as to whether the costs saved by the rebate contracts would not be significantly outweighed.

Diagnostic and prognostic value of uric acid in patients with acute dyspnea.

Am J Med. 2009 Nov; 122(11): 1054.e7-1054.e14
Reichlin T, Potocki M, Breidthardt T, Noveanu M, Hartwiger S, Burri E, Klima T, Stelzig C, Laule K, Mebazaa A, Christ M, Mueller C

BACKGROUND: Uric acid was shown to predict outcome in patients with stable chronic heart failure. Its impact in patients admitted in the Emergency Department with acute dyspnea, however, remains unknown. METHODS: We prospectively investigated the diagnostic and prognostic value of uric acid in 743 unselected patients presenting to the Emergency Department with acute dyspnea. RESULTS: Uric acid at admission was higher in patients with acute decompensated heart failure (51% of the cohort) as compared with patients with noncardiac causes of dyspnea (median, 447 micromol/L vs 340 micromol/L, P <.001). The area under the receiver operating characteristic curve for the accuracy to detect acute decompensated heart failure was inferior for uric acid (0.70) than for B-type natriuretic peptide (area under the receiver operating characteristic curve 0.91, P <.001). Patients in the highest uric acid tertile more often required admission to the hospital (92% vs 74% in the first tertile, P <.001) and had higher in-hospital mortality (13% vs 4% in the first tertile, P <.001). Cumulative 24-month mortality rates were 28% in the first, 31% in the second, and 50% in the third tertile (P <.001). After adjustment in multivariable Cox proportional hazard analysis, uric acid predicted 24-month mortality independently of B-type natriuretic peptide (P=.003). CONCLUSIONS: Our study first shows that uric acid, measured at Emergency Department admission or hospital discharge, is a powerful predictor of long-term outcome in dyspneic patients.

The emerging characterization of lysine residue deacetylation on the modulation of mitochondrial function and cardiovascular biology.

Circ Res. 2009 Oct 23; 105(9): 830-41
Lu Z, Scott I, Webster BR, Sack MN

There is emerging recognition of a novel fuel and redox sensing regulatory program that controls cellular adaptation via nonhistone protein lysine residue acetyl posttranslation modifications. This program functions in tissues with high energy demand and oxidative capacity and is highly enriched in the heart. Deacetylation is regulated by NAD(+)-dependent activation of the sirtuin family of proteins, whereas acetyltransferase modifications are controlled by less clearly delineated acetyltransferases. Subcellular localization specific protein targets of lysine-acetyl modification have been identified in the nucleus, cytoplasm, and mitochondria. Despite distinct subcellular localizations, these modifications appear, in large part, to modify mitochondrial properties including respiration, energy production, apoptosis, and antioxidant defenses. These mitochondrial regulatory programs are important in cardiovascular biology, although how protein acetyl modifications effects cardiovascular pathophysiology has not been extensively explored. This review will introduce the role of nonhistone protein lysine residue acetyl modifications, discuss their regulation and biochemistry and present the direct and indirect data implicating their involvement in the heart and vasculature.

[Hepatic adverse effects of allopurinol]

Lakartidningen. 2009 Sep 16-22; 106(38): 2374-5
Lindh J

[56-year-old patient with leg paresis, pulmonary infiltrates, and eosinophilia--Case 08/2009]

Dtsch Med Wochenschr. 2009 Oct; 134(44): 2228
Henes J, Horger M, Kanz L, Kötter I

HISTORY AND ADMISSION FINDINGS: A 56-year-old woman presented with progressive dyspnea and polyneuropathia. Medical history revealed a bronchial asthma and hypertension. She was in a reduced general condition and had to be admitted to the intensive care unit for mechanical ventilation the same day. INVESTIGATIONS: The computed tomography of the chest revealed distinct pulmonary infiltrates. Laboratory findings showed significantly elevated inflammatory markers as well as an eosinophilia in the differential blood count and the bronchial lavage. Diagnostics for infections were all negative as were antinuclear and anti-neutrophil cytoplasmatic antibodies (ANCAs). DIAGNOSIS, TREATMENT AND COURSE: An ANCA negative Churg Strauss Syndrome (CSS) was diagnosed in accordance with extravascular and blood eosinophilia, pulmonary infiltrates and the neurological symptoms. Aggressive therapy with high dose glucocorticosteroids and cyclophosphamide (CYC) pulses was initiated. The patient improved rapidly and was extubated 6 days after the initiation of treatment. After 6 cycles of CYC with 750 mg/m2 and a maintenance treatment with azathioprine and 5mg prednisolone the patient is still in complete remission 2,5 years after the diagnosis. CONCLUSION: The CSS belongs to the ANCA-associated vasculitides. The patient described here presented with all the characteristic organ involvements of CSS and a fulminate worsening. The fast diagnosis and aggressive therapy which was started only hours after admission to the intensive care unit induced a long lasting remission.

Meta- and pooled analyses of the methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism and colorectal cancer: a HuGE-GSEC review.

Am J Epidemiol. 2009 Nov 15; 170(10): 1207-21
Taioli E, Garza MA, Ahn YO, Bishop DT, Bost J, Budai B, Chen K, Gemignani F, Keku T, Lima CS, Le Marchand L, Matsuo K, Moreno V, Plaschke J, Pufulete M, Thomas SB, Toffoli G, Wolf CR, Moore CG, Little J

Worldwide, over 1 million cases of colorectal cancer (CRC) were reported in 2002, with a 50% mortality rate, making CRC the second most common cancer in adults. Certain racial/ethnic populations continue to experience a disproportionate burden of CRC. A common polymorphism in the 5,10-methylenetetrahydrofolate reductase (MTHFR) gene has been associated with a lower risk of CRC. The authors performed both a meta-analysis (29 studies; 11,936 cases, 18,714 controls) and a pooled analysis (14 studies; 5,068 cases, 7,876 controls) of the C677T MTHFR polymorphism and CRC, with stratification by racial/ethnic population and behavioral risk factors. There were few studies on different racial/ethnic populations. The overall meta-analysis odds ratio for CRC for persons with the TT genotype was 0.83 (95% confidence interval (CI): 0.77, 0.90). An inverse association was observed in whites (odds ratio = 0.83, 95% CI: 0.74, 0.94) and Asians (odds ratio = 0.80, 95% CI: 0.67, 0.96) but not in Latinos or blacks. Similar results were observed for Asians, Latinos, and blacks in the pooled analysis. The inverse association between the MTHFR 677TT polymorphism and CRC was not significantly modified by smoking status or body mass index; however, it was present in regular alcohol users only. The MTHFR 677TT polymorphism seems to be associated with a reduced risk of CRC, but this may not hold true for all populations.

Relationship between plasma uridine and urinary urea excretion.

metabolism. 2009 Oct 19;
Ka T, Inokuchi T, Tamada D, Suda M, Tsutsumi Z, Okuda C, Yamamoto A, Takahashi S, Moriwaki Y, Yamamoto T

To investigate whether the concentration of uridine in plasma is related to the urinary excretion of urea, 45 healthy male subjects with normouricemia and normal blood pressure were studied after providing informed consent. Immediately after collection of 24-hour urine, blood samples were drawn after an overnight fast except for water. The contents of ingested foods during the 24-hour urine collection period were described by the subjects and analyzed by a dietician. Simple regression analysis showed that plasma uridine was correlated with the urinary excretions of urea (R = 0.41, P < .01), uric acid (R = 0.36, P < .05), and uridine (R = 0.30, P < .05), as well as uric acid clearance (R = 0.35, P < .05) and Purine intake (R = 0.30, P < .05). In contrast, multiple regression analysis showed a positive relationship only between plasma uridine and urinary excretion of urea. These results suggest that an increase in de novo pyrimidine synthesis leads to an increased concentration of uridine in plasma via nitrogen catabolism in healthy subjects with normouricemia and normal blood pressure.

Ion channel regulation by AMPK: the route of hypoxia-response coupling in thecarotid body and pulmonary artery.

Ann N Y Acad Sci. 2009 Oct; 1177: 89-100
Evans AM, Hardie DG, Peers C, Wyatt CN, Viollet B, Kumar P, Dallas ML, Ross F, Ikematsu N, Jordan HL, Barr BL, Rafferty JN, Ogunbayo O

Vital homeostatic mechanisms monitor O2 supply and adjust respiratory and circulatory function to meet demand. The pulmonary arteries and carotid bodies are key systems in this respect. Hypoxic pulmonary vasoconstriction (HPV) aids ventilation-perfusion matching in the lung by diverting blood flow from areas with an O2 deficit to those rich in O2, while a fall in arterial pO2 increases sensory afferent discharge from the carotid body to elicit corrective changes in breathing patterns. We discuss here the new concept that hypoxia, by inhibiting oxidative phosphorylation, activates AMP-activated protein kinase (AMPK) leading to consequent phosphorylation of target proteins, such as ion channels, which initiate pulmonary artery constriction and carotid body activation. Consistent with this view, AMPK knockout mice exhibit an impaired ventilatory response to hypoxia. Thus, AMPK may be sufficient and necessary for hypoxia-response coupling and may regulate O2 and thereby energy (ATP) supply at the whole body as well as the cellular level.

Mitochondrial metabolism and cancer.

Ann N Y Acad Sci. 2009 Oct; 1177: 66-73
Weinberg F, Chandel NS

Historically, it has been assumed that glycolytic metabolism, not mitochondrial metabolism, is essential for tumor cell proliferation. However, most tumor cells have functional mitochondria, and recent studies suggest that the citric acid cycle (TCA) cycle intermediates are precursors for synthesis of nucleotides, lipids, and amino acids. Here we review the accumulating evidence that mitochondrial metabolism plays an essential role in tumor cell proliferation.

The role of KATP channels on propofol preconditioning in a cellular model of renal ischemia-reperfusion.

Anesth Analg. 2009 Nov; 109(5): 1486-92
Assad AR, Delou JM, Fonseca LM, Villela NR, Nascimento JH, Verçosa N, Lopes AG, Capella MA

BACKGROUND: Propofol (2,6-diisopropylphenol) has been shown to protect several organs, including the kidneys, from ischemia-reperfusion (I-R)-induced injury. Although propofol affects adenosine triphosphate-sensitive potassium (K(ATP)) channels in nonrenal tissues, it is still not clear by which mechanisms propofol protects renal cells from such damage. In this study, we investigated whether propofol induces renal preconditioning through renal K(ATP) channels. METHODS: A reversible ATP depletion (antimycin A) followed by restoration of substrate supply in LLC-PK1 cells was used as an in vitro model of renal I-R. Cell viability was assessed by dimethylthiazol-diphenyltetrazol bromide and trypan blue dye exclusion test assays. Apoptosis was evaluated by annexin V-fluorescein isothiocyanate staining by flow cytometry and immunofluorescence. Propofol treatments were initiated at various time intervals: 1 or 24 h before ischemia, only during ischemia, or only during reperfusion. To evaluate the mechanisms of propofol protection, specific K(ATP) channel inhibitors or activators were used in some experiments during propofol pretreatment. RESULTS: Propofol attenuated I-R injury on LLC-PK1 cells when present either 1 or 24 h before initiated I-R, and also during the recovery period, but not when added only during ischemia. Propofol pretreatment significantly protected LLC-PK1 from I-R-induced apoptosis. The protective effect of propofol was prevented by glibenclamide (a sarcolemmal ATP-dependent K(+) channel blocker) and decreased by 5-hydroxidecanoic acid (a mitochondrial ATP-dependent K(+) channel blocker), but it was not modified by diazoxide (a selective opener of ATP-sensitive K(+) channel). CONCLUSION: Propofol protected cells against apoptosis induced by I-R. This protection was probably due to a preconditioning effect of propofol and was, at least in part, mediated by K(ATP) channels.

The DEAD box helicase YxiN maintains a closed conformation during ATP hydrolysis.

Biochemistry. 2009 Nov 17; 48(45): 10679-81
Aregger R, Klostermeier D

DEAD box helicases unwind RNA duplexes at the expense of ATP hydrolysis. Recently, unwinding has been demonstrated in the absence of ATP hydrolysis. Herein, we show that ADP.BeF(x) supports RNA unwinding by YxiN, a DEAD box helicase that specifically recognizes a hairpin in 23S rRNA. ADP.AlF(x) and ADP.MgF(x) do not promote RNA unwinding, but all ATP analogues induce a closed conformation of the helicase core as required for RNA unwinding. Our results show that the interdomain cleft in the helicase core closes upon ATP binding at the beginning of the cycle. Reopening occurs after ATP hydrolysis, most likely coupled to phosphate release.